CD4+CD25+ Regulatory T-Cell Therapy for Allergy, Autoimmune Disease and Transplant Rejection

Author(s): Shuiping Jiang, Robert I. Lechler

Journal Name: Inflammation & Allergy - Drug Targets (Discontinued)
Formerly Current Drug Targets - Inflammation & Allergy

Volume 5 , Issue 4 , 2006


Naturally occurring CD4+CD25+ regulatory T cells (Tregs) play a critical role in the control of periphery tolerance to self-antigens. Interestingly, they also control immune responses to allergens and transplant antigens. Recent studies in animal models have shown that adoptive transfer of CD4+CD25+ Tregs can prevent or even cure allergic and autoimmune diseases, and appear to induce transplantation tolerance. Thus, adoptive cell therapy using patient-specific CD4+CD25+ Tregs has been emerged as individualized medicine for the treatment of inflammatory disease including allergy, autoimmune disease and transplant rejection. Furthermore, strategies to activate and expand antigen-specific CD4+CD25+ Tregs in vivo using pharmacological agents may represent a novel avenue for drug development.

Keywords: CD4+CD25+ regulatory T cells, FoxP3, adoptive cell therapy, antigen-specificity, allergy, autoimmune disease, transplantation tolerance, pharmacological agents

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2006
Page: [239 - 242]
Pages: 4
DOI: 10.2174/187152806779010981
Price: $58

Article Metrics

PDF: 3